Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 2,634 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intermediate dose Clear all
Completed Not applicable Interventional Results available

tDCS Plus Virtual Reality for PTSD

NCT03372460
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Active stimulation, Sham stimulation, Virtual Reality (VR)
Device · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 27, 2026, 4:16 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Alcohol and Mood on Attention

NCT04276779
View directory record Official record
Conditions
Suicidal Ideas
Interventions
Alcohol administration, Placebo administration, Positive mood induction, Negative mood induction
Other · Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 27, 2026, 4:16 PM EDT
Recruiting Phase 1 Interventional

Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection

NCT07275905
View directory record Official record
Conditions
Cystic Fibrosis (CF), Achromobacter Infection
Interventions
AchromoPhage
Biological
Lead sponsor
Ghady Haidar
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 27, 2026, 4:16 PM EDT
Recruiting Phase 1 Interventional

PSMA PET Response Guided SabR in High Risk Pca

NCT06044857
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
68-Ga PSMA11
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 27, 2026, 4:16 PM EDT
Not yet recruiting Not applicable Interventional

Dynamic, Real-world Learning, Innovative Mobility, and Versatile Exploration (DRIVE): Evaluating a Dose-matched Developmental Powered Mobility Intervention for Young Children With Cerebral Palsy

NCT07876219
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Permobil Explorer Mini, MORE-PT
Device · Other
Lead sponsor
University of Washington
Other
Eligibility
12 Months to 33 Months
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
Grand Rapids, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 27, 2026, 4:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants

NCT02833831
View directory record Official record
Conditions
Healthy
Interventions
ALS-008176, Placebo, Moxifloxacin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 27, 2026, 4:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Gene Therapy for Achromatopsia (CNGA3)

NCT03758404
View directory record Official record
Conditions
Achromatopsia
Interventions
adeno-associated virus vector AAV- CNGA3
Biological
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
3 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 27, 2026, 4:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.

NCT06139991
View directory record Official record
Conditions
Heathy Participants
Interventions
Treatment A (BDA MDI HFO), Treatment B (BDA MDI HFA)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 27, 2026, 4:16 PM EDT
Completed Phase 4 Interventional Results available

Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking

NCT02995915
View directory record Official record
Conditions
Smoking Cessation, Alcohol Drinking
Interventions
Nicotine Replacement Therapy, Bupropion, Cognitive Behavioral Treatment, Mobile Contingency Management, Mobile Monitoring
Other · Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 27, 2026, 4:16 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

NCT02316106
View directory record Official record
Conditions
Multiple Myeloma
Interventions
daratumumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
15
States / cities
Little Rock, Arkansas • Jacksonville, Florida • West Palm Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 27, 2026, 4:16 PM EDT
Recruiting Phase 1 Interventional

Study of Treatment for HPV16+ ASC-US or LSIL

NCT03913117
View directory record Official record
Conditions
ASC-US, LSIL
Interventions
pNGVL4aCRTE6E7L2, TA-CIN
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 27, 2026, 4:16 PM EDT
Completed Phase 3 Interventional Results available

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

NCT00929110
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Glycopyrronium bromide, Placebo to glycopyrronium bromide, Tiotropium
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
1,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2012 · Synced Oct 27, 2026, 4:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects

NCT03150108
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
rhPTH(1-84)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 27, 2026, 4:16 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Intravenous Ketamine Effects on Functional Neuroanatomy

NCT04205890
View directory record Official record
Conditions
Depression
Interventions
Ketamine
Drug
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 27, 2026, 4:16 PM EDT
Recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 27, 2026, 4:16 PM EDT
Terminated Phase 4 Interventional Results available

Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)

NCT05228184
View directory record Official record
Conditions
Congenital Hypothyroidism
Interventions
Tirosint®-SOL, Levothyroxine Sodium
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
1 Day to 9 Months
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 27, 2026, 4:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study Between Bosutinib And Dabigatran

NCT02102633
View directory record Official record
Conditions
Healthy
Interventions
Dabigatran, Bosutinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 27, 2026, 4:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Brown Adipose Tissue Activation on Insulin Sensitivity in Humans

NCT01791114
View directory record Official record
Conditions
Insulin Sensitivity, Obesity
Interventions
Cold exposure, Cold exposure plus propranolol, Thermoneutral Conditions, Cold water consumption, Tepid water consumption, Exercise, Meal consumption
Other
Lead sponsor
Rutgers University
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 27, 2026, 4:16 PM EDT
Completed Phase 3 Interventional Results available

A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity

NCT01852058
View directory record Official record
Conditions
Urinary Incontinence
Interventions
OnabotulinumtoxinA
Biological
Lead sponsor
Allergan
Industry
Eligibility
5 Years to 17 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 27, 2026, 4:16 PM EDT
Completed Phase 4 Interventional Results available

Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)

NCT00458835
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Ciclesonide
Drug
Lead sponsor
Covis Pharma S.à.r.l.
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 27, 2026, 4:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)

NCT01970176
View directory record Official record
Conditions
Cardiomyopathy, Renal Impairment
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 27, 2026, 4:16 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

NCT05357898
View directory record Official record
Conditions
Adult Solid Tumor
Interventions
SQZ-eAPC-HPV, Pembrolizumab
Biological
Lead sponsor
SQZ Biotechnologies
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
9
States / cities
Scottsdale, Arizona • Duarte, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 27, 2026, 4:16 PM EDT
Not yet recruiting Not applicable Interventional

Feasibility of a Dyadic Music-based Intervention for Persons Living With Dementia and Their Care Partners

NCT07843043
View directory record Official record
Conditions
Dementia
Interventions
Dyadic Music-based Intervention (MBI), Reminiscence Activity
Behavioral
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 27, 2026, 4:16 PM EDT
Withdrawn Phase 1 Interventional

IVIG in Acute Ischemic Stroke: A Pilot Study

NCT01628055
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Privigen, Normal Saline
Biological · Other
Lead sponsor
Inova Health Care Services
Other
Eligibility
45 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 27, 2026, 4:16 PM EDT